These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23787697)

  • 21. Immunological mimicry of PrPC-PrPSc interactions: antibody-induced PrP misfolding.
    Li L; Guest W; Huang A; Plotkin SS; Cashman NR
    Protein Eng Des Sel; 2009 Aug; 22(8):523-9. PubMed ID: 19602568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prion protein misfolding.
    Kupfer L; Hinrichs W; Groschup MH
    Curr Mol Med; 2009 Sep; 9(7):826-35. PubMed ID: 19860662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping of possible prion protein self-interaction domains using peptide arrays.
    Rigter A; Langeveld JP; Timmers-Parohi D; Jacobs JG; Moonen PL; Bossers A
    BMC Biochem; 2007 Apr; 8():6. PubMed ID: 17430579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of bovine spongiform encephalopathy, ovine scrapie prion-related protein (PrPSc) and normal PrPc by monoclonal antibodies raised to copper-refolded prion protein.
    Thackray AM; Madec JY; Wong E; Morgan-Warren R; Brown DR; Baron T; Bujdoso R
    Biochem J; 2003 Feb; 370(Pt 1):81-90. PubMed ID: 12429022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prion protein-specific antibodies-development, modes of action and therapeutics application.
    Rovis TL; Legname G
    Viruses; 2014 Oct; 6(10):3719-37. PubMed ID: 25275428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conservation of a glycine-rich region in the prion protein is required for uptake of prion infectivity.
    Harrison CF; Lawson VA; Coleman BM; Kim YS; Masters CL; Cappai R; Barnham KJ; Hill AF
    J Biol Chem; 2010 Jun; 285(26):20213-23. PubMed ID: 20356832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The H187R mutation of the human prion protein induces conversion of recombinant prion protein to the PrP(Sc)-like form.
    Hosszu LL; Tattum MH; Jones S; Trevitt CR; Wells MA; Waltho JP; Collinge J; Jackson GS; Clarke AR
    Biochemistry; 2010 Oct; 49(40):8729-38. PubMed ID: 20718410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanopore analysis reveals differences in structural stability of ovine PrP(C) proteins corresponding to scrapie susceptible (VRQ) and resistance (ARR) genotypes.
    Madampage CA; Marciniuk K; Määttänen P; Cashman NR; Potter A; Lee JS; Napper S
    Prion; 2013; 7(6):511-9. PubMed ID: 24401607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity.
    Wei X; Roettger Y; Tan B; He Y; Dodel R; Hampel H; Wei G; Haney J; Gu H; Johnstone BH; Liu J; Farlow MR; Du Y
    J Biol Chem; 2012 Apr; 287(16):12858-66. PubMed ID: 22362783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state.
    Horiuchi M; Caughey B
    EMBO J; 1999 Jun; 18(12):3193-203. PubMed ID: 10369660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process?
    Igel-Egalon A; Bohl J; Moudjou M; Herzog L; Reine F; Rezaei H; Béringue V
    Viruses; 2019 May; 11(5):. PubMed ID: 31083283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing misfolding of the prion protein by trimethylamine N-oxide.
    Bennion BJ; DeMarco ML; Daggett V
    Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic peptide vaccines yield monoclonal antibodies to cellular and pathological prion proteins of ruminants.
    Harmeyer S; Pfaff E; Groschup MH
    J Gen Virol; 1998 Apr; 79 ( Pt 4)():937-45. PubMed ID: 9568991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure.
    Cobb NJ; Sönnichsen FD; McHaourab H; Surewicz WK
    Proc Natl Acad Sci U S A; 2007 Nov; 104(48):18946-51. PubMed ID: 18025469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathologic prion protein infects cells by lipid-raft dependent macropinocytosis.
    Wadia JS; Schaller M; Williamson RA; Dowdy SF
    PLoS One; 2008; 3(10):e3314. PubMed ID: 19390657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prion Protein-Antibody Complexes Characterized by Chromatography-Coupled Small-Angle X-Ray Scattering.
    Carter L; Kim SJ; Schneidman-Duhovny D; Stöhr J; Poncet-Montange G; Weiss TM; Tsuruta H; Prusiner SB; Sali A
    Biophys J; 2015 Aug; 109(4):793-805. PubMed ID: 26287631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro neutralization of prions with PrP(Sc)-specific antibodies.
    Taschuk R; Van der Merwe J; Marciniuk K; Potter A; Cashman N; Griebel P; Napper S
    Prion; 2015; 9(4):292-303. PubMed ID: 26284508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of conformation-dependent prion protein epitopes.
    Kang HE; Weng CC; Saijo E; Saylor V; Bian J; Kim S; Ramos L; Angers R; Langenfeld K; Khaychuk V; Calvi C; Bartz J; Hunter N; Telling GC
    J Biol Chem; 2012 Oct; 287(44):37219-32. PubMed ID: 22948149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterisation of new monoclonal antibodies reacting with prions from both human and animal brain tissues.
    Cordes H; Bergström AL; Ohm J; Laursen H; Heegaard PM
    J Immunol Methods; 2008 Sep; 337(2):106-20. PubMed ID: 18657541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying key components of the PrPC-PrPSc replicative interface.
    Abalos GC; Cruite JT; Bellon A; Hemmers S; Akagi J; Mastrianni JA; Williamson RA; Solforosi L
    J Biol Chem; 2008 Dec; 283(49):34021-8. PubMed ID: 18826953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.